The multivariate HR for a low expression of CD204+TAMs was 0.44 (1/0.44 = 2.27) indicating a 2.27 times significantly lower chance of tumour recurrence compared with patients with a high expression of CD204+TAMs, when controlled for CD204 and subtype of treatment modality (p = 0.038) (Table 7). This evidence concerns the gene MSR1 and neoplasm.